Breaking News
Get 50% Off 0
😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingPro CLAIM SALE
Close

Teva Pharma Industries Ltd ADR (TEVA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Teva ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.59 +0.09    +0.55%
- Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 196,581
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.50 - 16.59
Teva ADR 16.59 +0.09 +0.55%

TEVA Recent Sentiments

 
This page contains information on users’ sentiments for the Teva Pharma Industries Ltd ADR stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Jul 24, 2024 דוד מורסיאנו   16.59 0.00%
Jul 24, 2024 דורון שוקרון   16.63 -0.24%
Jul 23, 2024 מוטי עמית   17.00 -2.41%
Jul 23, 2024 רפי הבר   17.13 -3.15%
Jul 23, 2024 אבי אשכנזי   17.11 -3.04%
Jul 23, 2024 אלפונסו ואתורי   16.96 +2.18%
Jul 22, 2024 Ronen Mirkov   17.10 -2.98%
Jul 22, 2024 גבריאל אסור   17.15 -3.27%
Jul 22, 2024 אליהו שרגא   17.05 -2.70%
Jul 22, 2024 שמואל טוטיאן   17.09 -2.93%
Jul 22, 2024 דוד חילוץ   17.08 -2.87%
Jul 19, 2024 Hhvt Bvvg   16.38 Jul 22, 2024 @ 17.06 -4.15%
Jul 18, 2024 אייל בכר   16.36 -1.41%
Jul 18, 2024 יואל רוזנברג   16.38 +1.28%
Jul 18, 2024 עמי רביוד   16.50 +0.55%
Jul 18, 2024 משה פדידה   16.52 Jul 22, 2024 @ 17.06 +3.27%
Jul 17, 2024 שלמה אהרוני   16.34 +1.53%
Jul 17, 2024 יניב הינדי   16.42 -1.04%
Jul 17, 2024 שלמה אהרוני   16.55 Jul 17, 2024 @ 16.53 -0.12%
Jul 17, 2024 שמואל טוטיאן   16.67 Jul 22, 2024 @ 17.09 +2.52%
Jul 16, 2024 Peder Nielsen   16.89 Jul 16, 2024 @ 16.90 +0.06%
Jul 16, 2024 Israel fridman   17.18 -3.43%
Jul 16, 2024 James Simonton   17.19 -3.49%
Jul 15, 2024 יוסי אלצטר   17.07 +2.81%
Jul 15, 2024 ירמי משה   17.04 +2.64%
Jul 15, 2024 אבי פלד   17.08 -2.87%
Jul 15, 2024 עדי דוד   17.05 -2.70%
Jul 15, 2024 eli shwartz   17.03 -2.58%
Jul 15, 2024 יהונתן בנימין   17.30 Jul 22, 2024 @ 17.06 -1.39%
Jul 15, 2024 רפי מנטין   17.25 -3.83%
Jul 15, 2024 ציון אנדרי בן שושן   17.03 Jul 15, 2024 @ 17.27 +1.41%
Jul 12, 2024 שמואל טוטיאן   17.26 Jul 15, 2024 @ 17.27 +0.06%
Jul 12, 2024 שלמה אהרוני   17.15 Jul 17, 2024 @ 16.54 +3.56%
Jul 11, 2024 Preben Secher...   17.16 -3.32%
Jul 10, 2024 Zion Hason   16.93 -2.01%
Jul 10, 2024 leon fink   16.93 +2.01%
Jul 10, 2024 ניסים עזרא   16.76 -1.01%
Jul 10, 2024 יובל סוויסה   16.56 -0.18%
Jul 10, 2024 Bella Danilov   15.81 Jul 15, 2024 @ 17.27 +9.23%
Jul 10, 2024 Brian Christensen   15.80 Jul 15, 2024 @ 17.27 +9.30%
Jul 09, 2024 Amnon Hilel   15.84 +4.73%
Jul 09, 2024 צבי מרציאנו   15.88 Jul 15, 2024 @ 17.27 -8.75%
Jul 09, 2024 Tal Shvartzman   15.91 +4.27%
Jul 09, 2024 malrm malrm   16.01 Jul 15, 2024 @ 17.27 +7.87%
Jul 09, 2024 israel gross   16.46 Jul 15, 2024 @ 17.27 +4.92%
Jul 08, 2024 Ofer Moshe   16.44 Jul 15, 2024 @ 17.27 -5.05%
Jul 08, 2024 ניב מימון   16.37 +1.34%
Jul 08, 2024 ציון דוד   16.45 Jul 15, 2024 @ 17.27 +4.98%
Jul 08, 2024 צביקה קגנסקי   16.45 +0.85%
Jul 08, 2024 משה פדידה   16.52 Jul 15, 2024 @ 17.27 +4.54%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TEVA Comments

Write your thoughts about Teva Pharma Industries Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
TSahi Livnoni
TSahi Livnoni Jun 27, 2024 8:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Glen Santangelo from Jefferies, Buy, 23$
TSahi Livnoni
TSahi Livnoni Jun 14, 2024 5:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
All new price targets are buy and above 20$-21$
TSahi Livnoni
TSahi Livnoni May 09, 2024 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Post er the average of the new price targets is 19$ Nice. This will continue all the way to 30, 40$.
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
One day to ER of Q1
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New price target of 17$ by Barclays analyst
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
TSahi Livnoni
TSahi Livnoni Mar 23, 2024 9:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1% on a Friday with 9.13M volume someone is buying.
TSahi Livnoni
TSahi Livnoni Mar 13, 2024 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
simple story of debt reduction and value going up. revenue growth will set the pace will move up in the next 2-3 years to about 30-40$
ritchie lee
ritchie lee Jan 22, 2024 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
long trend starting
Ramba Łej
Kubizm Jan 22, 2024 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hopefully ! Ive been w8ing for it for 3 y xD
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email